Nuvation Bio is a biopharmaceutical company developing therapies for oncology, addressing difficult-to-treat cancers.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Stanley Druckenmiller / Duquesne | 91 | New buy | 4,539,800 | $19,476 | 0.6% |
| David Einhorn / Greenlight | 50 | Holds (flat) | 34,995 | $150,129 | 0.0% |
| ABRAMS CAPITAL MANAGEMENT, L.P. (auto-surfaced) | 85 | Trimmed -67% | 1,270,504 | $5,450,462 | 0.1% |
| Report | Date | Stance |
|---|---|---|
| #97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami | 2025-05-28 | LONG |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-20.